Valuation of Early Stage Biotech Companies "Net Present Value versus VC approach" Wednesday, March 29th, 2017 Swiss HLG and BaselArea.swiss are excited to present the Swiss HLG's latest start-up workshop collaboration. We will explore the value of science vs. the value of cash in the valuation of a Biotech company.The risk-adjusted, net present value […]